Skip to main content

Advertisement

Log in

Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model

  • Original Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Minimal physiologically based pharmacokinetic (mPBPK) models provide a simple and sensible approach that incorporates physiological elements into pharmacokinetic (PK) analysis when only plasma data are available. With this modeling concept, a second-generation mPBPK model was further developed with specific accommodations for the unique PK properties of monoclonal antibodies (mAb). This study applied this model to extensively survey mAb PK in man in order to seek general perspectives on mAb distributional and elimination features. Profiles for 72 antibodies were successfully analyzed with this model. The model results provide assessment regarding: (1) predominant clearance site, in plasma or interstitial fluid (ISF); (2) mAb ISF concentrations in two groups of lumped tissues with continuous (V tight ) or fenestrated (V leaky ) vascular endothelium; (3) Transcapillary escape rate (TER), an indicator of systemic vascular permeability. For 93 % of surveyed mAbs, the model assuming clearance from plasma (CL p ) produced better or at least equivalent model performance than the model with clearance from ISF and yielded most consistent values of vascular reflection coefficients (σ1 and σ2) among all antibodies. The average mAb ISF concentration in V tight and V leaky at equilibrium was predicted to be about 6.8 and 37.9 % of that in plasma. A positive correlation was detected between plasma clearance and TER among most mAbs, which could be interpreted as both parameters having common determinants related to ISF tissue distribution in this model context. The mAbs with relative higher plasma clearance (>0.035 L/h/70 kg) did not reveal such positive correlation between clearance and TER, implying that the factors contributing to high clearance may not necessarily increase tissue distribution and penetration. In conclusion, this mPBPK model offers a more mechanistic approach for analyzing plasma mAb PK than compartment models and generates parameters providing useful intrinsic distributional and elimination insights for a large number of mAbs that were examined in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413–415

    Google Scholar 

  2. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192–1198

    Article  CAS  PubMed  Google Scholar 

  3. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301–316

    Article  CAS  PubMed  Google Scholar 

  4. Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403–449

    CAS  PubMed  Google Scholar 

  5. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548–558

    Article  CAS  PubMed  Google Scholar 

  6. Richter WF, Grimm HP, Theil FP (2011) Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components. J Pharmacokinet Pharmacodyn 38:581–593

    Article  CAS  PubMed  Google Scholar 

  7. Garzone PD, Atkinson AJ Jr (2012) In search of physiologically based distribution volume estimates for macromolecules. Clin Pharmacol Ther 92:419–421

    Article  CAS  PubMed  Google Scholar 

  8. Cao Y, Jusko WJ (2012) Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 39:711–723

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Cao Y, Balthasar JP, Jusko WJ (2013) Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn 40:597–607

    Article  CAS  PubMed  Google Scholar 

  10. Sarin H (2010) Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2:14

    Article  PubMed Central  PubMed  Google Scholar 

  11. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687–709

    Article  CAS  PubMed  Google Scholar 

  12. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67–86

    Article  CAS  PubMed  Google Scholar 

  13. Wagshul ME, Johnston M (2013) The brain and the lymphatic system. Immunology of the Lymphatic System. Springer, New York, pp 143–164

    Chapter  Google Scholar 

  14. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095

    Article  CAS  PubMed  Google Scholar 

  15. Stucker O, Pons-Himbert C, Laemmel E (2008) Towards a better understanding of lymph circulation. Phlebolymphology. 15:31–36

    Google Scholar 

  16. Wiig H, Tenstad O (2001) Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. Am J Physiol Heart Circ Physiol 280:H1505–H1512

    CAS  PubMed  Google Scholar 

  17. Wiig H, Kaysen GA, al-Bander HA, De Carlo M, Sibley L, Renkin EM (1994) Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. Am J Physiol 266:H212–H219

    CAS  PubMed  Google Scholar 

  18. D’Argenio DZ, Schumitzky A (2009) ADAPT V User’s Guide: Pharmacokinetic/Pharmacodynamic System Analysis Software. Biomedical Simulations Resource, Los Angeles

    Google Scholar 

  19. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21:2153–2163

    Article  CAS  PubMed  Google Scholar 

  20. Davies PF, Ross R (1978) Mediation of pinocytosis in cultured arterial smooth muscle and endothelial cells by platelet-derived growth factor. J Cell Biol 79:663–671

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA (2012) Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 14:554–558

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861–2871

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Golay J, Semenzato G, Rambaldi A, Foa R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5:826–837

    Article  PubMed Central  PubMed  Google Scholar 

  24. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH (2006) Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 12:6517–6522

    Article  CAS  PubMed  Google Scholar 

  25. Cao YG and Jusko WJ (2014) Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. doi:10.1007/s10928-014-9372-2

Download references

Acknowledgments

This research was supported by the National Institutes of Health Grant GM57980 and the UB Center for Protein Therapeutics.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William J. Jusko.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 35 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cao, Y., Jusko, W.J. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J Pharmacokinet Pharmacodyn 41, 571–580 (2014). https://doi.org/10.1007/s10928-014-9374-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-014-9374-0

Keywords

Navigation